Published in J Carcinog on January 01, 2009
Reactive oxygen species-mediated apoptosis contributes to chemosensitization effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells. J Exp Clin Cancer Res (2010) 1.13
BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. Int J Cancer (2011) 1.08
Plant terpenes: defense responses, phylogenetic analysis, regulation and clinical applications. 3 Biotech (2014) 0.93
Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer. Curr Drug Targets (2010) 0.89
The effect of carvacrol on healthy neurons and N2a cancer cells: some biochemical, anticancerogenicity and genotoxicity studies. Cytotechnology (2013) 0.83
GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Mol Cancer (2015) 0.83
Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles. ACS Nano (2015) 0.81
Plasma metabolomic profiles of breast cancer patients after short-term limonene intervention. Cancer Prev Res (Phila) (2014) 0.81
Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapy. Cancer Nanotechnol (2016) 0.80
Synergistic inhibitory effect of berberine and d-limonene on human gastric carcinoma cell line MGC803. J Med Food (2014) 0.78
Role of D-Limonene in autophagy induced by bergamot essential oil in SH-SY5Y neuroblastoma cells. PLoS One (2014) 0.77
Reversing translational suppression and induction of toxicity in pancreatic cancer cells using a chemoprevention gene therapy approach. Mol Pharmacol (2014) 0.77
The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomes. J Oncol (2011) 0.77
Decatropis bicolor (Zucc.) Radlk essential oil induces apoptosis of the MDA-MB-231 breast cancer cell line. BMC Complement Altern Med (2016) 0.75
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
The GTPase superfamily: conserved structure and molecular mechanism. Nature (1991) 19.64
The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Prooxidant states and tumor promotion. Science (1985) 6.26
Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell (1999) 3.14
Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J (1999) 3.00
Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst (1997) 1.81
Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer (2005) 1.62
Docetaxel: a review of its use in metastatic breast cancer. Drugs (2005) 1.47
D-Limonene: safety and clinical applications. Altern Med Rev (2007) 1.33
Cancer of the prostate. Crit Rev Oncol Hematol (2005) 1.31
Overcoming multidrug resistance in taxane chemotherapy. Clin Chem Lab Med (2002) 1.25
Tea beverage in chemoprevention of prostate cancer: a mini-review. Nutr Cancer (2003) 1.23
Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res (2000) 1.23
Update on chemoprevention of prostate cancer. Curr Opin Urol (2004) 1.18
Limonene-induced regression of mammary carcinomas. Cancer Res (1992) 1.15
Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int (2005) 1.13
Chemistry and chemical biology of taxane anticancer agents. Chem Rec (2001) 1.12
Reactive oxygen and nitrogen species: efficient, selective, and interactive signals during intercellular induction of apoptosis. Anticancer Res (2001) 1.11
Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol (1998) 1.10
Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol (2001) 1.06
Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells. BMC Cancer (2005) 1.04
Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor beta 1 levels during monoterpene-induced regression of mammary tumors. Cancer Res (1993) 1.03
Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther (2008) 1.03
Inhibition of DMBA-induced mammary cancer by the monoterpene d-limonene. Carcinogenesis (1984) 1.02
Mechanisms of action of taxanes in prostate cancer. Semin Oncol (1999) 0.97
Docetaxel (taxotere) in the treatment of prostate cancer. Expert Rev Anticancer Ther (2003) 0.97
Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells. J Cell Physiol (2008) 0.94
Novel drug amooranin induces apoptosis through caspase activity in human breast carcinoma cell lines. Breast Cancer Res Treat (2003) 0.92
Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. Br J Cancer (2007) 0.91
Inhibition by d-limonene of experimental hepatocarcinogenesis in Sprague-Dawley rats does not involve p21(ras) plasma membrane association. Int J Cancer (2001) 0.85
TNF-alpha and IL-1alpha induce apoptosis in subconfluent rat mesangial cells. Evidence for the involvement of hydrogen peroxide and lipid peroxidation as second messengers. Cytokine (2000) 0.85
Evidence for the association of ultraviolet-C and H(2)O(2)-induced apoptosis with acid sphingomyelinase activation. Biochim Biophys Acta (2001) 0.85
d-Limonene inhibits N-nitrosobis(2-oxopropyl)amine induced hamster pancreatic carcinogenesis. Cancer Lett (1997) 0.84
Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer (2007) 0.81
Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. Semin Oncol (1997) 0.80
Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. World J Hepatol (2011) 1.17
Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies. Biochem Pharmacol (2013) 1.15
Terpenoids and breast cancer chemoprevention. Breast Cancer Res Treat (2008) 1.07
Bystander effects caused by nonuniform distributions of DNA-incorporated (125)I. Micron (2002) 1.07
Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents. Expert Rev Neurother (2010) 1.03
Nrf2-mediated redox signaling in arsenic carcinogenesis: a review. Arch Toxicol (2012) 1.00
Curcumin and liver cancer: a review. Curr Pharm Biotechnol (2012) 0.96
Modulation of angiogenesis by dietary phytoconstituents in the prevention and intervention of breast cancer. Mol Nutr Food Res (2011) 0.94
Ocimum sanctum Linn. (Tulsi): an ethnomedicinal plant for the prevention and treatment of cancer. Anticancer Drugs (2013) 0.92
Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer. Nutr Cancer (2013) 0.92
Curcumin and neurodegenerative diseases: a perspective. Expert Opin Investig Drugs (2012) 0.91
Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr Drug Targets (2012) 0.91
The health benefits of blackcurrants. Food Funct (2012) 0.88
Alteration of hepatic proinflammatory cytokines is involved in the resveratrol-mediated chemoprevention of chemically-induced hepatocarcinogenesis. Curr Pharm Biotechnol (2012) 0.87
Pomegranate Bioactive Constituents Suppress Cell Proliferation and Induce Apoptosis in an Experimental Model of Hepatocellular Carcinoma: Role of Wnt/ β -Catenin Signaling Pathway. Evid Based Complement Alternat Med (2013) 0.87
Anticancer potential of aloes: antioxidant, antiproliferative, and immunostimulatory attributes. Planta Med (2012) 0.84
Sequential activation of Elk-1/Egr-1/GADD45α by arsenic. Oncotarget (2014) 0.83
Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma. Invest New Drugs (2009) 0.82
Selenium in the prevention and treatment of hepatocellular carcinoma. Anticancer Agents Med Chem (2010) 0.82
Black currant anthocyanins abrogate oxidative stress through Nrf2- mediated antioxidant mechanisms in a rat model of hepatocellular carcinoma. Curr Cancer Drug Targets (2012) 0.81
Green tea and the risk of gastric cancer: epidemiological evidence. World J Gastroenterol (2013) 0.81
Resveratrol exerts differential effects in vitro and in vivo against ovarian cancer cells. Asian Pac J Cancer Prev (2012) 0.81
Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J Drug Target (2010) 0.80
Antitumor activities of extracts from selected desert plants against HepG2 human hepatocellular carcinoma cells. Pharm Biol (2013) 0.80
Suppression of inflammatory cascade is implicated in methyl amooranin-mediated inhibition of experimental mammary carcinogenesis. Mol Carcinog (2013) 0.79
Anticancer attributes of desert plants: a review. Anticancer Drugs (2012) 0.79
Simultaneous disruption of estrogen receptor and Wnt/β-catenin signaling is involved in methyl amooranin-mediated chemoprevention of mammary gland carcinogenesis in rats. Mol Cell Biochem (2013) 0.78
Potential role of targeted therapies in the treatment of triple-negative breast cancer. Anticancer Drugs (2016) 0.77
Can Probiotics Cure Inflammatory Bowel Diseases? Curr Pharm Des (2016) 0.77
Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review. Anticancer Drugs (2015) 0.77
Multi-targeting Andrographolide and its natural analogs as potential therapeutic agents. Curr Top Med Chem (2016) 0.77
5-Lipoxygenase and cyclooxygenase inhibitory dammarane triterpenoid 1 from Borassus flabellifer seed coat inhibits tumor necrosis factor-α secretion in LPSInduced THP-1 human monocytes and induces apoptosis in MIA PaCa-2 pancreatic cancer cells. Anticancer Agents Med Chem (2015) 0.76
Phytochemicals potently inhibit migration of metastatic breast cancer cells. Integr Biol (Camb) (2015) 0.76
Cancer preventive and curative attributes of plants of the Cactaceae family: a review. Planta Med (2013) 0.76
Natural products of dietary origin as lead compounds in virtual screening and drug design. Curr Pharm Biotechnol (2012) 0.76
Editorial: recent advances in the prevention and therapy of hepatocellular carcinoma. Curr Cancer Drug Targets (2012) 0.76
Editorial: current advances in cancer prevention and treatment by natural products. Curr Pharm Biotechnol (2012) 0.76